Global Plasmid
DNA Manufacturing Market, by Product Type (High Quality (HQ) Plasmid DNA,
GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by Application (DNA
Vaccines, Gene Therapy, Immunotherapy, and Others), and by Region (North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was
valued at US$ 65.1 million in 2017 and is projected to exhibit a CAGR of 23.7%
over the forecast period (2018 – 2026).
Increased research and development
activity is expected to augment the market growth Key players in the market are
focused on research & development, expansion, and collaboration activities
in order to enhance their market share. For instance, in January 2019, Sarepta
Therapeutics, Inc. and Aldevron announced their collaboration. This
collaboration provided Sarepta with Aldevron’s manufacturing slots and capacity
for production of GMP grade plasmid for its various programs related to gene
therapy. For instance, in January 2019, Sarepta Therapeutics, Inc. collaborated
with Aldevron to supply GMP grade plasmids, in order to cater to the demand of
Sarepta’s gene therapy clinical trials and for commercial supply. Moreover, in
April 2018, PlasmidFactory GmbH & Co. KG announced the acquisition of new
laboratory space to expand research and development activities and production
of plasmid DNA. This strategic move was taken, owing to increasing demand for
High Quality (HQ) Grade DNA production.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2593
Browse 36 Market Data Tables and
32 Figures spread through 149 Pages and in-depth TOC on ‘Plasmid DNA
Manufacturing Market’- Global Forecast to 2026, by Product Type (High Quality
(HQ) Plasmid DNA, GMP Grade Plasmid DNA, and Non-GMP Grade Plasmid DNA), by
Application (DNA Vaccines, Gene Therapy, Immunotherapy, and Others), and by
Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa)
Key players in the market are
focused on adopting strategies such as mergers and acquisitions to enhance
their product portfolio. For instance, in February 2016, Agilis
Biotherapeutics, LLC (Agilis) and Waisman Biomanufacturing entered into an
exclusive partnership agreement for the production of Agilis’ novel gene
therapy product, AGIL-FA, for the treatment of Friedreich’s ataxia (FA).
Similarly, in March 2019, Aldevron announced expansion plan for antibody
development platform facility in Germany. This expansion plan will add around
4,300 square feet of production and laboratory space to current facility.
Browse Research
Report: https://www.coherentmarketinsights.com/market-insight/plasmid-dna-manufacturing-market-2593
Key Takeaways of the Plasmid DNA
Manufacturing Market:
The global plasmid DNA
manufacturing market is expected to exhibit a CAGR of 23.7% over the forecast
period, owing to increasing demand for plasmid (pDNA) DNA
Among product type, the high
quality plasmid DNA segment held dominant position in the plasmid DNA
manufacturing market in 2017, owing to increased usage of higher quality
plasmid DNA in biotechnology research and vaccine production
Among application, immunotherapy
segment held dominant position in the plasmid DNA manufacturing market in 2017,
owing to high adoption rate of immunotherapy
Key players operating in the
global plasmid DNA manufacturing market include Cobra Biologics and
Pharmaceutical Services, VGXI, Inc., Aldevron, Kaneka Corporation, Nature
Technology Corporation, PlasmidFactory GmbH & Co. KG, Cell and Gene Therapy
Catapult, and Waisman Biomanufacturing
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2593
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment